Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
Open Access
- 1 March 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 13, 909-924
- https://doi.org/10.2147/dddt.s189847
Abstract
Vaccines for Pseudomonas aeruginosa have been of longstanding interest to immunologists, bacteriologists, and clinicians, due to the widespread prevalence of hospital-acquired infection. As P. aeruginosa becomes increasingly antibiotic resistant, there is a dire need for novel treatments and preventive vaccines. Despite intense efforts, there currently remains no vaccine on the market to combat this dangerous pathogen. This article summarizes current and past vaccines under development that target various constituents of P. aeruginosa. Targeting lipopolysaccharides and O-antigens have shown some promise in preventing infection. Recombinant flagella and pili that target TLR5 have been utilized to combat P. aeruginosa by blocking its motility and adhesion. The type 3 secretion system components, such as needle-like structure PcrV or exotoxin PopB, are also potential vaccine targets. Outer membrane proteins including OprF and OprI are newer representatives of vaccine candidates. Live attenuated vaccines are a focal point in this review, and are also considered for novel vaccines. In addition, phage therapy is revived as an effective option for treating refractory infections after failure with antibiotic treatment. Many of the aforementioned vaccines act on a single target, thus lacking a broad range of protection. Recent studies have shown that mixtures of vaccines and combination approaches may significantly augment immunogenicity, thereby increasing their preventive and therapeutic potential.Keywords
This publication has 147 references indexed in Scilit:
- Pseudomonas aeruginosa Syntrophy in Chronically Colonized Airways of Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2012
- Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth LarvaeApplied and Environmental Microbiology, 2012
- The Bacterial Cell EnvelopeCold Spring Harbor Perspectives in Biology, 2010
- Bacteriophage Cocktail for the Prevention of Biofilm Formation by Pseudomonas aeruginosa on Catheters in an In Vitro Model SystemAntimicrobial Agents and Chemotherapy, 2010
- Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on Neisseria lactamica Outer Membrane VesiclesClinical and Vaccine Immunology, 2009
- Type VI secretion system translocates a phage tail spike-like protein into target cells where it cross-links actinProceedings of the National Academy of Sciences of the United States of America, 2007
- A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patientsProceedings of the National Academy of Sciences of the United States of America, 2007
- TLR4-dependent adjuvant activity of Neisseria meningitidis lipid AVaccine, 2007
- Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infectionsProceedings of the National Academy of Sciences of the United States of America, 2007
- Genetics of susceptibitlity to human infectious diseaseNature Reviews Genetics, 2001